Paroxetine CR (paroxetine hydrochloride controlled-release tablets) is the first new formulation of SSRIs. It was developed by Geomatrix oral drug delivery technology. It results in 4 to 5 hours absorption lag, relatively smooth plasma paroxetine concentrations with low peak-to-through fluctuation at steady state. Paroxetine CR has been permitted by FDA with indications of major depression, panic disorder, premenstrual dysphoric disorder and anxiety disorder. Compared to the other immediate-release SSRIs, paroxetine CR has not only good efficacy but also better tolerability and thus can reduce the risk of medication discontinuation and change during the treatment. Paroxetine CR can improve the compliance of treatment and make better outcome. Therefore paroxetine CR provides a new valuable option to treat patients with major depression.
NETL
NSTL
维普
万方数据
